Unknown

Dataset Information

0

Convalescent plasma transfusion therapy in severe and critical COVID-19 patients: A Systematic Review and Meta-Analysis


ABSTRACT:

Background

Convalescent plasma treatment for severe and critically ill Corona Virus Disease 2019 (COVID-19) patients remains controversial.

Objective

To evaluate the clinical improvement and mortality risk of convalescent plasma treatment in patients with severe and critically ill COVID-19 patients.

Methods

A literature search was conducted in the electronic databases for the randomized controlled studies about convalescent plasma therapy in severe and critically ill COVID-19 patients. Two reviewers independently extracted relevant data. The primary outcomes were clinical improvement and mortality risk of severe and critically ill COVID-19 patients that were therapied by convalescent plasma.

Results

A total of 14 randomized controlled trials with 4543 patients were included in this meta-analysis. Compared to control, no significant difference was observed for either clinical improvement (6 studies, RR 1.07, 95% CI 0.97 to 1.17, p = 0.16, moderate certainty) or mortality risk (14 studies, RR 0.94, 95% CI 0.85 to 1.03, p= 0.18, low certainty) in patients of convalescent plasma therapy group.

Conclusion

Convalescent plasma did not increase the clinical improvement or reduce the mortality risk in the severe and critically ill COVID-19 patients.

SUBMITTER: Yang P 

PROVIDER: S-EPMC8806131 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8652389 | biostudies-literature
| S-EPMC1976638 | biostudies-literature
| S-EPMC8295978 | biostudies-literature
| S-EPMC3877008 | biostudies-literature
| S-EPMC6531101 | biostudies-literature
| S-EPMC7101507 | biostudies-literature
| S-EPMC7848881 | biostudies-literature
| S-EPMC4057299 | biostudies-literature
| S-EPMC8502250 | biostudies-literature